Todos Medical Announces Saliva-Only MonkeyPox Test
Post# of 1418
(Total Views: 268)
Posted On: 08/26/2022 9:13:46 AM
Todos Medical Announces Saliva-Only MonkeyPox Testing at CLIA/CAP Clinical Lab Provista Diagnostics
Lab Reaching Out to Georgia-based School
Administrators to Assist with Outbreak Plans
NEW YORK, NY and TEL AVIV, Israel, Aug. 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its Atlanta-area CLIA/CAP-certified clinical laboratory Provista Diagnostics, Inc. is now offering saliva-only MonkeyPox testing. The saliva-based samples collected must be stored in the refrigerator within 1 hour of collection and be shipped with cold packs to arrive at the lab within 72 hours of sample collection. The lab has a result turnaround time of 24-48h from the time the sample arrives at the lab. The sensitivity achieved for the saliva-based MonkeyPox laboratory-developed test (LDT) is 1.2 viral copies per reaction (0.12 copies/ul). The saliva test is intended to be used primarily in suspected cases of MonkeyPox without lesions. In cases where patients with suspected MonkeyPox present with lesions, it is still recommended to test both lesions and saliva to determine whether the lesions contain virus and whether saliva is representative of systemic active infection. The Company’s sales representatives have begun reaching out to school districts in the Atlanta, Georgia area to make them aware of Provista’s saliva testing capabilities. The Provista saliva MonkeyPox test is available in all states, with the exception of New York. The Company expects to be able to offer MonkeyPox testing in New York following a late September inspection by the New York Department of Health (NYDOH).
“We believe the scaling up of pre-symptomatic MonkeyPox testing, before lesions fully develop that can be swabbed, represents a game-changing event in the nation’s ability to contain outbreaks of MonkeyPox,” said Gerald E. Commissiong, President & CEO of Todos Medical. “As a parent of a school age children, I would want to know the school had a plan to test everyone if there was even one case of MonkeyPox to get a handle on community spread. For decades MonkeyPox has not affected the United States because of quick containment. While there are challenges containing the spread outside the walls of the schoolyard, we have the tests available right now that could potentially identify community spread very early and mitigate the risks to our children. We owe it to our school age children to keep them safe because kids are at increased risk of severe outcomes from MonkeyPox.”
Provista is now also preparing to validate blood testing for MonkeyPox IgM/IgG antibodies, including collection using finger prick collection devices, as well as validating MonkeyPox fecal samples to identify potential viral persistence after resolution of acute MonkeyPox symptoms.
https://investor.todosmedical.com/news-events...testing-at
Lab Reaching Out to Georgia-based School
Administrators to Assist with Outbreak Plans
NEW YORK, NY and TEL AVIV, Israel, Aug. 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its Atlanta-area CLIA/CAP-certified clinical laboratory Provista Diagnostics, Inc. is now offering saliva-only MonkeyPox testing. The saliva-based samples collected must be stored in the refrigerator within 1 hour of collection and be shipped with cold packs to arrive at the lab within 72 hours of sample collection. The lab has a result turnaround time of 24-48h from the time the sample arrives at the lab. The sensitivity achieved for the saliva-based MonkeyPox laboratory-developed test (LDT) is 1.2 viral copies per reaction (0.12 copies/ul). The saliva test is intended to be used primarily in suspected cases of MonkeyPox without lesions. In cases where patients with suspected MonkeyPox present with lesions, it is still recommended to test both lesions and saliva to determine whether the lesions contain virus and whether saliva is representative of systemic active infection. The Company’s sales representatives have begun reaching out to school districts in the Atlanta, Georgia area to make them aware of Provista’s saliva testing capabilities. The Provista saliva MonkeyPox test is available in all states, with the exception of New York. The Company expects to be able to offer MonkeyPox testing in New York following a late September inspection by the New York Department of Health (NYDOH).
“We believe the scaling up of pre-symptomatic MonkeyPox testing, before lesions fully develop that can be swabbed, represents a game-changing event in the nation’s ability to contain outbreaks of MonkeyPox,” said Gerald E. Commissiong, President & CEO of Todos Medical. “As a parent of a school age children, I would want to know the school had a plan to test everyone if there was even one case of MonkeyPox to get a handle on community spread. For decades MonkeyPox has not affected the United States because of quick containment. While there are challenges containing the spread outside the walls of the schoolyard, we have the tests available right now that could potentially identify community spread very early and mitigate the risks to our children. We owe it to our school age children to keep them safe because kids are at increased risk of severe outcomes from MonkeyPox.”
Provista is now also preparing to validate blood testing for MonkeyPox IgM/IgG antibodies, including collection using finger prick collection devices, as well as validating MonkeyPox fecal samples to identify potential viral persistence after resolution of acute MonkeyPox symptoms.
https://investor.todosmedical.com/news-events...testing-at
(1)
(0)Todos Med Ltd. (TOMDF) Stock Research Links
Scroll down for more posts ▼